Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

EMA Recommends Extension of Therapeutic Indications for Axicabtagene Ciloleucel

New indication concerns the treatment of adult patients with relapsed or refractory follicular lymphoma
27 May 2022
Cell-Based Therapy
Lymphomas

On 22 April 2022, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product axicabtagene ciloleucel (Yescarta).

The marketing authorisation holder for this medicinal product is Kite Pharma EU B.V.

The CHMP adopted a new indication for the treatment of follicular lymphoma.

For information, the full indications for Yescarta will be as follows (new indication in bold):

Yescarta is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma, after two or more lines of systemic therapy.

Yescarta is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma after three or more lines of systemic therapy.

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics, which will be published in the revised European public assessment report and will be available in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.

Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.